POSTER: MM-510 Patient-Reported Outcomes in Patients With Relapsed or Refractory Multiple Myeloma (RRMM) Treated With Belantamab Mafodotin (Belamaf) Versus Pomalidomide Plus Low-Dose Dexamethasone (Pd) in the DREAMM-3 Study

Autor: Hungria, Vania, Weisel, Katja, Currie, Brooke, Perera, Sue, Sule, Neal, He, Wei, Davy, Katherine, McKeown, Astrid, Sapra, Sandhya, Nelsen, Linda, Li, Mary, Barale, Sophie, Boyle, Julia, McPoyle, Kaytlyn, Dimopoulos, Meletios Athanasios
Zdroj: In Clinical Lymphoma, Myeloma and Leukemia September 2023 23 Supplement 1:S224-S224
Databáze: ScienceDirect
Externí odkaz: